Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rociletinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | FER | P16591 | 1/20 | 1.00 |
| ▸ | ERBB3 | P21860 | 1/20 | 1.00 |
| ▸ | TEC | P42680 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 1/20 | 1.00 |
| ▸ | BTK | Q06187 | 1/20 | 1.00 |
| ▸ | TNK1 | Q13470 | 1/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 1/20 | 1.00 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rociletinib SCHEMBL4177736 | 1.00 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| Rociletinib SCHEMBL29350136 | 1.00 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| Rociletinib SCHEMBL30101824 | 0.99 | EGFR (0.99) | EGFRGAKFESFERERBB3 | |
| SCHEMBL4166347 | 0.97 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| SCHEMBL24900776 | 0.97 | EGFR (0.94) | EGFRGAKFESFERERBB3 | |
| SCHEMBL30221331 | 0.97 | EGFR (0.94) | EGFRGAKFESFERERBB3 | |
| SCHEMBL2730294 | 0.95 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| SCHEMBL4165883 | 0.94 | EGFR (1.00) | EGFRGAKFESFERERBB3 | |
| SCHEMBL16556502 | 0.93 | EGFR (0.87) | EGFRGAKFESFERERBB3 | |
| SCHEMBL2722575 | 0.93 | EGFR (1.00) | EGFRGAKFESFERERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4355330-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | Genentech, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| WO-2022265950-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | GENENTECH, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| US-12343428-B2 | Compositions and methods for cancer treatment | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-07-01 | — | — | US | disclosed |
| US-12304939-B2 | EGFR and C-met fibronectin type III domain binding molecules | JANSSEN BIOTECH, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | Accencio LLC (US) | 2025-04-15 | — | — | US | disclosed |
| CN-118141921-A | Use of CAMK2 inhibitors for the preparation of a medicament for reducing resistance to EGFR-driven cancers | 四川大学 | 2024-06-07 | — | — | CN | disclosed |
| EP-4355330-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | Genentech, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| WO-2022265950-A1 | EGFR INHIBITOR AND PERK ACTIVATOR IN COMBINATION THERAPY AND THEIR USE FOR TREATING CANCER | GENENTECH, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| EP-4023670-A1 | EGFR AND C-MET-FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES | Janssen Biotech, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | CAMP4 THERAPEUTICS CORPORATION | 2022-04-07 | — | — | US | disclosed |
| CN-109053595-B | Salts of epidermal growth factor receptor kinase inhibitors | 西建卡尔有限责任公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-108546300-B | Molecules that bind EGFR and C-MET fibronectin type III domain | 詹森生物科技公司 | 2022-03-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220107328-A1 | METHODS OF TREATING LIVER DISEASES | PNPLA2, LIPC, PNLIP | EGFR 4408/4885GAK 4285/4885FES 4544/4885 |
| US-12274700-B1 | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors | ACE, SARS1, EIF2AK2 | EGFR 1308/4885GAK 3223/4885FES 1958/4885 |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | EGFR 3/4885GAK 443/4885FES 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.